- Home
- BIIB vs CCL Comparison
BIIB vs CCL Comparison
Compare BIIB & CCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CCL
- Stock Information
- Founded
- BIIB 1978
- CCL 1972
- Country
- BIIB United States
- CCL United States
- Employees
- BIIB N/A
- CCL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CCL Marine Transportation
- Sector
- BIIB Health Care
- CCL Consumer Discretionary
- Exchange
- BIIB Nasdaq
- CCL Nasdaq
- Market Cap
- BIIB 18.8B
- CCL 22.4B
- IPO Year
- BIIB 1991
- CCL 1987
- Fundamental
- Price
- BIIB $134.15
- CCL $24.21
- Analyst Decision
- BIIB Buy
- CCL Buy
- Analyst Count
- BIIB 26
- CCL 17
- Target Price
- BIIB $194.95
- CCL $26.65
- AVG Volume (30 Days)
- BIIB 1.7M
- CCL 21.7M
- Earning Date
- BIIB 07-31-2025
- CCL 06-24-2025
- Dividend Yield
- BIIB N/A
- CCL N/A
- EPS Growth
- BIIB 26.39
- CCL 377.81
- EPS
- BIIB 10.12
- CCL 1.52
- Revenue
- BIIB $9,816,400,000.00
- CCL $25,424,000,000.00
- Revenue This Year
- BIIB N/A
- CCL $5.35
- Revenue Next Year
- BIIB N/A
- CCL $3.68
- P/E Ratio
- BIIB $13.31
- CCL $15.95
- Revenue Growth
- BIIB 1.59
- CCL 12.66
- 52 Week Low
- BIIB $110.04
- CCL $13.78
- 52 Week High
- BIIB $238.00
- CCL $28.72
- Technical
- Relative Strength Index (RSI)
- BIIB 62.26
- CCL 68.08
- Support Level
- BIIB $129.61
- CCL $21.62
- Resistance Level
- BIIB $134.74
- CCL $24.40
- Average True Range (ATR)
- BIIB 3.10
- CCL 0.58
- MACD
- BIIB 0.60
- CCL 0.02
- Stochastic Oscillator
- BIIB 86.90
- CCL 85.17
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CCL Carnival Corporation
Carnival is the largest global cruise company, with more than 90 ships in service at the end of fiscal 2024. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It's currently folding its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.